SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

admilparant

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Regulatory submissions for IPF have not yet been filed. If BMS submits an NDA in 2027, a potential FDA decision could come in 2028 under standard review, or sooner if Breakthrough Therapy Designation for PPF expedites the IPF review. The ALOFT-PPF readout in early 2027 will also inform the regulatory path.
Why 4/10
The next hard catalyst is the Phase 3 ALOFT-PPF topline readout in progressive pulmonary fibrosis, expected in early 2027 (no specific date yet). Admilparant is a meaningful pipeline asset but represents only a ~5% DCF swing factor for diversified large-cap BMY, limiting the stock-level impact of any single catalyst.
Actionable Insight NEUTRAL

Watch for the ALOFT-PPF topline readout in early 2027, which will determine whether admilparant can expand into the broader progressive pulmonary fibrosis market. A positive PPF result would strengthen the drug's commercial case ahead of planned regulatory submissions for IPF. Also monitor for any announced NDA submission date, which would set a PDUFA calendar.

Price Chart

Loading chart...

Executive Summary

Admilparant (BMS-986278) is Bristol Myers Squibb's investigational first-in-class oral LPA1 antagonist for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). On October 12, 2026, BMS announced that the pivotal Phase 3 ALOFT-IPF trial met its primary endpoint at the 60 mg twice-daily dose, showing a statistically significant improvement in lung function (FVC) versus placebo at 52 weeks, though the 120 mg dose missed statistical significance. The drug showed a favorable safety profile. BMS plans to engage with health authorities for regulatory submissions, though no NDA has been filed yet and no PDUFA date exists. A second Phase 3 trial (ALOFT-PPF) in progressive pulmonary fibrosis is fully enrolled with topline results expected in early 2027. For diversified large-cap BMY, admilparant represents a modest value driver (Goldman Sachs estimates ~5% DCF impact), with William Blair forecasting $1.3B in IPF sales by 2032.

How It Works

Admilparant is an experimental pill that blocks a protein called LPA1, which is involved in the scarring process in the lungs. By blocking this target, the drug aims to slow the progression of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), two serious lung-scarring diseases that make it progressively harder to breathe.

Trial Status

The Phase 3 ALOFT-IPF trial (IPF) has completed with positive topline results at 60 mg announced October 12, 2026. The Phase 3 ALOFT-PPF trial (progressive pulmonary fibrosis) is fully enrolled with topline results expected in early 2027. A long-term extension study is also ongoing.

The Two-Sided Case

▲ Bull Case5
Admilparant met its Phase 3 ALOFT-IPF primary endpoint at 60 mg with a statistically significant improvement in lung function (FVC) versus placebo at 52 weeks, supporting a potential first-in-class LPA1 antagonist approval.
The drug showed a favorable safety and tolerability profile with low adverse-event discontinuation rates comparable to placebo in the Phase 3 trial.
Admilparant has FDA Breakthrough Therapy Designation for PPF and Fast Track and Orphan Drug Designations for IPF, which could expedite review.
The drug is oral and twice-daily, offering a convenient dosing regimen. William Blair estimates peak sales of $1.3B in IPF by 2032, while Goldman Sachs modeled ~$2.7B unadjusted peak sales by 2035.
A fully enrolled Phase 3 ALOFT-PPF trial in progressive pulmonary fibrosis could expand the addressable market if topline results due in early 2027 are positive.
▼ Bear Case5
The 120 mg dose failed to show statistical significance in ALOFT-IPF, raising questions about dose response and the drug's therapeutic window. Leerink called the findings 'mixed' and downgraded BMY.
Liver safety concerns emerged during the program, including a patient death and a 'limited number' of liver-related events that led to a protocol amendment, though causality is unclear.
The IPF market already has three approved therapies (pirfenidone, nintedanib, nerandomilast), and admilparant would need to differentiate on efficacy, safety or convenience to capture share.
Competing LPA1 antagonists are in development from Contineum Therapeutics (PIPE-791) and AbbVie (ABBV-142), which could crowd the target class.
Goldman Sachs modeled admilparant as only a ~5% DCF swing factor for BMY, meaning even a successful launch would have limited impact on the stock of this large-cap pharma.

Upcoming Catalysts

  • Phase 3 ALOFT-PPF topline results in progressive pulmonary fibrosis (early 2027)
  • Regulatory submissions (NDA/MAA) for IPF following engagement with health authorities (timeline not specified)
  • Presentation of full ALOFT-IPF data at a future medical meeting

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 14

Hover a chip for the title
1 en.wikipedia.org2 news.bms.com3 reuters.com4 biopharmadive.com5 biospace.com6 fiercebiotech.com7 businesswire.com8 news.bms.com9 finvaulta.com10 tipranks.com11 pharmaphorum.com12 trialfriend.com13 allsci.com14 ajmc.com